anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cyaonoside A (CyA), derived from the natural Chinese medicine, Cyathula officinalis Kuan, which was for a long time used to treat knee injuries and relieve joint pain in traditional Chinese medicine, showed an unclear mechanism for protecting cartilage. In addition, CyA was poorly hydrosoluble and incapable of being injected directly into the joint cavity, which limited its clinical application. This study reveals that CyA resisted IL-1β-mediated chondrogenic inflammation and apoptosis. Next, transcriptome sequencing is used to explore the potential mechanisms underlying CyA regulation of MSC chondrogenic differentiation. Based on these findings, CyA-loaded composite hydrogel microspheres (HLC) were developed and they possessed satisfactory loading efficiency, a suitable degradation rate and good biocompatibility. HLC increased chondrogenic anabolic gene (Acan, COL2A, and SOX9) expression, while downregulating the expression of the catabolic marker MMP13 in vitro. In the osteoarthritis mouse model, HLC demonstrated promising therapeutic capabilities by protecting the integrity of articular cartilage. In conclusion, this study provides insights into the regulatory mechanisms of CyA for chondrocytes and proposes a composite hydrogel microsphere-based advanced therapeutic strategy for osteoarthritis.
The invention discloses an enema for treating radiation proctitis. The radiation proctitis belongs to categories of diarrhea and dysentery of traditional Chinese medicine. The causes of the radiation proctitis are insufficient of healthy qi, downward flow of damp-heat, asthenia in origin and asthenia in superficiality, and the radiation proctitis and the causes interact as both cause and effect. Consequently, the enema is made of traditional Chinese medicine narcissus, salvia chinensis, meadowrue root and rhizome, semen cassia, Chinese toona root-barks, trollflowers, beautyberry leaves, Japanese thistle herbs, lotus leaves, pagoda tree pods, mulberries, bighead atractylodes thizome, longan seeds and honey which have the functions of clearing away heat and toxic materials, subsiding a swelling and stopping bleeding, and replenishing qi and enriching blood. Through clinical tests of a hospital, total effective rate of a treatment group is 91.3% and is superior to that, which is 78.3%, of a control group. The enema for treating radiation proctitis has no side effect and is worth of clinical popularization and application.
The precise mapping of collateral circulation and ischemic penumbra is crucial for diagnosing and treating acute ischemic stroke (AIS). Unfortunately, there exists a significant shortage of high-sensitivity and high-resolution in vivo imaging techniques to fulfill this requirement. Herein, a contrast enhanced susceptibility-weighted imaging (CE-SWI) using the minimalist dextran-modified Fe3O4 nanoparticles (Fe3O4@Dextran NPs) are introduced for the highly sensitive and high-resolution AIS depiction under 9.4 T for the first time. The Fe3O4@Dextran NPs are synthesized via a simple one-pot coprecipitation method using commercial reagents under room temperature. It shows merits of small size (hydrodynamic size 25.8 nm), good solubility, high transverse relaxivity (r2) of 51.3 mM-1s-1 at 9.4 T, and superior biocompatibility. The Fe3O4@Dextran NPs-enhanced SWI can highlight the cerebral vessels readily with significantly improved contrast and ultrahigh resolution of 0.1 mm under 9.4 T MR scanner, enabling the clear spatial identification of collateral circulation in the middle cerebral artery occlusion (MCAO) rat model. Furthermore, Fe3O4@Dextran NPs-enhanced SWI facilitates the precise depiction of ischemia core, collaterals, and ischemic penumbra post AIS through matching analysis with other multimodal MR sequences. The proposed Fe3O4@Dextran NPs-enhanced SWI offers a high-sensitivity and high-resolution imaging tool for individualized characterization and personally precise theranostics of stroke patients.
Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.
Pulverulent or granular non-saponaceous wetting agents, cleansing agents or dentifrices are agglomerated by mixing therewith an aqueous solution of a gum or other mucilaginous substance and precipitating the gum &c. by means of an anhydrous salt which is capable of forming hydrated cystals by abstracting water of crystallisation from the water of the solution, the amount of water in the latter in relation to the amount of anhydrous salt being not more than the amount required to hydrate the anhydrous salt completely.  This latter proportion of water may be less than the amount required to hydrate the anhydrous salt completely.  Anhydrous alkali sulphates are specified particularly anhydrous sodium sulphate.  The materials treated comprise the substances known under the Registered Trade Marks "Lorol," "Gardinol," "Fewa," and "Teepol."  The mucilaginous substances specified comprise Shiraz gum, water-soluble alkyl celluloses, cellulose ethers and alginates.  The cleansing agents &c. may contain a small proportion of an alkaline compound such as sodium borate or trisodium phosphate so as to render the pH value comparable to that of ordinary soap, perfumes, dyes or pigments, or usual fillers such as kaolin.  The cool solidified mass may be shaped into tablets, flakes, noodles, strings, &c. Specification 418,846 is referred to.ALSO:Pulverulent or granular non-saponaceous wetting agents which may be used as cleansing agents and dentifrices are agglomerated by mixing therewith an aqueous solution of a gum or other mucilaginous substance and precipitating the gum &c. by means of an anhydrous salt which is capable of forming hydrated crystals by abstracting water of crystallization from the water of the solution, the amount of water in the latter in relation to the amount of anhydrous salt being not more than the amount required to hydrate the anhydrous salt completely.  This latter proportion of water may be less than the amount required to hydrate the anhydrous salt completely.  Anhydrous alkali sulphates are specified, particularly anhydrous sodium sulphate.  The materials treated comprise the substances known under the Registered Trade Marks "Lorol," "Gardinol," "Fewa" and "Teepol."  The mucilaginous substances specified comprise Shiraz gum, water-soluble alkyl celluloses, cellulose ethers and alginates. The wetting agents may contain a small proportion of an alkaline compound such as sodium borate or trisodium phosphate so as to render the pH value comparable to that of ordinary soap, perfumes, dyes or pigments, or usual fillers such as kaolin.  The cool solidified mass may be shaped into tables, flakes, noodles, strings, &c.  Specification 418,846 is referred to.
This study aims to assess the feasibility and efficacy of the digital therapeutic attention bias modification (ABM) intervention that targets and reduces negative attention bias among adults with elevated symptoms of depression. Consistent with the experimental therapeutics approach ABM has been shown to both reduce negative attention bias and improve symptoms of depression. However, engagement with these tasks have been mixed, with some participants describing traditional ABM tasks as boring. This had led to the development of gamified versions of ABM with the intent to improve participant engagement. Nevertheless, there have been very few rigorous trials of ABM for depression, and no one to our knowledge has used ecological momentary assessment to tease apart the mechanisms by which ABM can lead to improvements in depression symptoms.

Participants will access the intervention on their mobile smart phone and complete treatment over a period of 4 weeks. Enrolled participants will be randomly assigned to one of two groups: Gamified attention bias modification training, or gamified placebo training. They will complete brief (\~5 questions) daily surveys, as well as weekly remote assessments of attention bias and depression symptoms.
PURPOSE:To enhance stability of endoplasmic reticulum by polymerizing endoplasmic reticulum consisting of the raw material for a capsule contg. polymerizable phospholipid compd., thereafter freeze-drying it to obtain powdery material and dispersing this in an aq. medium to reconstitute endoplasmic reticulum. CONSTITUTION:Endoplasmic reticulum is formed by applying an ultrasonic irradiation method and a French press method, etc., to a microcapsule material contg. polymerizable phospholipid compd. After polymerizing this endoplasmic reticulum by using ultraviolet rays irradiation and radiation irradiation, etc. this polymerized endoplasmic reticulum is freeze-dried with an ordinary method to make it powdery. Then the structure of endoplasmic reticulum is reconstituted by dispersing this freeze-dried polymerized material again into an aq. medium. Further in the case of using phospholipid compd. having one polymerizable group at a time of polymerization even when endoplasmic reticulum is reconstituted by adding the polymerizable phospholipid compd. and subjected to postcross-link, the stability of endoplasmic reticulum can be similarly enhanced.
Sepsis is defined as "a life-threatening organ dysfunction caused by a dysregulated host response to infection". Although the treatment of sepsis has evolved rapidly in the last few years, the morbidity and mortality of sepsis in clinical treatment are still climbing. Sirtuins (SIRTs) are a highly conserved family of histone deacetylation involved in energy metabolism. There are many mechanisms of sepsis-induced myocardial damage, and more and more evidence show that SIRTs play a vital role in the occurrence and development of sepsis-induced myocardial damage, including the regulation of sepsis inflammation, oxidative stress and metabolic signals. This review describes our understanding of the molecular mechanisms and pathophysiology of sepsis-induced myocardial damage, with a focus on disrupted SIRTs regulation. In addition, this review also describes the research status of related therapeutic drugs, so as to provide reference for the treatment of sepsis.
PURPOSE:To provide the title pharmaceutical useful for the therapy of gingivostomatitis produced during cancer therapies, comprising allopurinol, carboxymethylcellulose or its water-soluble salt and water. CONSTITUTION:1 pt.wt. of allopurinol and 5-50 pts.wt. of carboxymethylcellulose or its water-soluble salt are well-ground and mixed using e.g. a mortar, 100-2000 pts.wt. of water is then added to the mixture followed by agitation. The product is then passed through a 50-mesh sieve followed by, if needed, addition of sterilized purified water, thus obtaining the objective pharmaceutical. The concentration of the allopurinol is, based on the whole pharmaceutical, 0.2mg/100ml to 5mg/100ml.
BACKGROUND/OBJECTIVE: Laryngeal electromyography (LEMG) is a useful diagnostic test in the evaluation of vocal fold paralysis (VFP). This study investigates factors that can make LEMG challenging to perform.
METHODS: Patients with subacute unilateral VFP presented for LEMG were prospectively enrolled. Demographic data including BMI, previous neck surgery, and anatomic factors were collected. Patient-reported pain related to the procedure was recorded on a visual analogue scale (VAS). Electromyographer and otolaryngologist recorded a consensus rating of the perceived difficulty in performing the test and confidence in using the results for clinical decision-making.
RESULTS: A total of 111 patients (56.8% female) were enrolled between August 2015 and August 2018. The mean age was 55 ± 14 years, and the average body mass index (BMI) was 28.5 ± 6.4. The mean patient-reported VAS score for pain was 35 ± 24. Notably, 31.2% of the tests were considered "very easy," 32.1% were considered "mildly challenging" and 23.9% and 12.8% were considered "moderately challenging" and "extremely challenging," respectively, by the clinicians. Common factors affecting LEMG difficulty included poorly palpable surface anatomy (50.5%) and patient intolerance (15.6%). Clinicians felt confident in 76.1% of the test findings. Bivariate analyses showed that prior neck surgery is associated with elevated VAS (p = 0.02), but clinician-perceived difficulty of performing the test is not associated with elevated VAS scores (p = 0.55).
CONCLUSIONS: Majority of LEMG tests are well tolerated by patients. Physicians reported more confidence using LEMG for clinical decision-making when the test was easier to perform. Difficult surface anatomy and patient intolerance affects clinician confidence in integrating the test results with clinical care.
LEVEL OF EVIDENCE: 3 Laryngoscope, 134:831-834, 2024.
One of the complications of allogeneic stem cell transplant (ASCT) is graft versus host disease (GVHD). This is when the donor cells that are infused attack the body organs. This can cause serious illness and even death. The chance of getting serious life threatening GVHD with conventional transplant conditioning regimens is 25-50% depending on whether the donor bone marrow is from a family member or an unrelated person. The reduced intensity conditioning regimen used in this study involves a drug called pentostatin as well as a reduced dose of radiation and a treatment called photopheresis. This regimen has been successfully used in 106 patients. The incidence of serious GVHD in those patients was much less than expected: 8% for patients getting bone marrow from a family member and 23% for those getting bone marrow from an unrelated person. The pentostatin and radiation parts of this reduced intensity conditioning regimen are similar to other types of reduced intensity regimens, which use drugs similar to pentostatin. The unique part of this regimen compared to others is the use of extracorporeal photopheresis (ECP).

While ECP has been used in 106 patients as part of a reduced intensity conditioning regimen, it is unknown whether adding ECP to pentostatin and radiation is what caused the reduced rate of GVHD that was seen in the previous study that was done. The use of ECP as part of a conditioning regimen is investigational. ECP is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma, but is not approved by the FDA for use prior to ASCT.

Because it is not known whether the use of ECP in the reduced intensity conditioning regimen was what caused the low incidence of GVHD, this research study will look at differences in getting GVHD based on whether you receive ECP. Half the patients in this research study will receive ECP as part of their reduced intensity-conditioning regimen and the other half will not. Patients will be randomized (50% chance you will receive ECP and 50% chance you will not). Both groups will receive pentostatin and reduced dose total body irradiation. The primary purpose of this research study is to look at the chance of developing serious GVHD within the first 100 days after transplant within each group.
This is a phase II Simon two-stage single-center study of concurrent fecal microbiota transplang (FMT) with pembrolizumab in patients with PD-1 resistant/refractory melanoma. The study will be conducted over a 12-week period (and up to 24-weeks in responding patients).

Patient eligibility is based upon prior exposure to PD-1 inhibitor therapy and response at first (or subsequent) restaging scans from week 12 up to week 52. Patients must have received a minimum of 2 cycles to be considered eligible. Patients who have received either nivolumab or pembrolizumab are eligible. Patients who have received pembrolizumab/nivolumab in combination with other investigational agent(s) may be eligible at the discretion of the treating investigator. PD-1 refractory disease is defined as progressive disease (PD) at the first (or subsequent) radiographic evaluation while receiving PD-1 inhibitor treatment as assessed by RECIST v1.1 on a restaging scan. Other eligibility criteria include absence of CNS disease, presence of disease amenable to biopsy and lack of contra-indications to FMT administration. Patients will be stratified on the presence or absence of liver metastases.

Suitable patients will be identified following first (or subsequent) restaging study that documents progressive disease (RECIST v1.1). Patients will undergo a screening evaluation consisting of imaging (including CNS if clinically suspected), tumor biopsy, and serological/stool studies to confirm suitability for FMT administration. Eligible patients will receive FMT endoscopically (along with intestinal biopsy) (with cycle 1 pembrolizumab +/- 3 days) followed by 3 further cycles of pembrolizumab (cycles 2-4) following which restaging will be performed. Patients with stable and/or responding disease will continue to receive pembrolizumab on study for 4 cycles. Patients with stable and/or responding disease after 8 cycles of pembrolizumab will continue to receive therapy off study until disease progression or up to two years from FMT administration.
Osteoarthritis (OA) management remains challenging because of its intricate pathogenesis. Intra-articular injections of drugs, such as glucocorticoids and hyaluronic acid (HA), have certain limitations, including the risk of joint infection, pain, and swelling. Hydrogel-based therapeutic strategies have attracted considerable attention because of their enormous therapeutic potential. Herein, a supramolecular nanofiber hydrogel is developed using dexamethasone sodium phosphate (DexP) as a vector to deliver lentivirus-encoding hyaluronan synthase 2 (HAS2) (HAS2@DexP-Gel). During hydrogel degradation, HAS2 lentivirus and DexP molecules are slowly released. Intra-articular injection of HAS2@DexP-Gel promotes endogenous HA production and suppresses synovial inflammation. Additionally, HAS2@DexP-Gel reduces subchondral bone resorption in the anterior cruciate ligament transection-induced OA mice, attenuates cartilage degeneration, and delays OA progression. HAS2@DexP-Gel exhibited good biocompatibility both in vitro and in vivo. The therapeutic mechanisms of the HAS2@DexP-Gel are investigated using single-cell RNA sequencing. HAS2@DexP-Gel optimizes the microenvironment of the synovial tissue by modulating the proportion of synovial cell subpopulations and regulating the interactions between synovial fibroblasts and macrophages. The innovative nanofiber hydrogel, HAS2@DexP-Gel, effectively enhances endogenous HA production while reducing synovial inflammation. This comprehensive approach holds promise for improving joint function, alleviating pain, and slowing OA progression, thereby providing significant benefits to patients.
Chronic neck pain has become a more prevalent musculoskeletal disorder in modern society. The prevalence of chronic neck pain in 2021 gradually increases to 45.7%, that results in a large burden of health care. Chronic neck pain leads to neck motion limitation, motor control impairment and unsmooth motion. In addition, faulty breathing pattern has been identified in 83% of people with chronic neck pain. Diaphragm is the most critical muscle for inspiration and also plays an important role in spinal stability that might relate to spinal instability and pain. Studies have proved that effects of diaphragmatic resistance training on reduce pain and improving quality of life in people with low back pain. Diaphragm connects to the lumbar spine and also to the cervical spine through the fascial, neural and visceral system. However, to our best knowledge, the effects of diaphragmatic resistance training in people with chronic neck pain is still unclear. While many studies have demonstrated that cervical stabilization exercises are able to decrease pain and disability and improve movement quality, the effects of combined diaphragmatic resistance training and cervical stabilization exercise in people with chronic neck pain is still unknown. Therefore, the purpose of this study is to investigate the effects of 6 weeks of diaphragmatic resistance training in combination with cervical stabilization exercises in people with chronic neck pain. Participants with chronic neck pain will be randomly assigned to either (1) combined diaphragmatic resistance training and cervical stabilization exercise group or (2) cervical stabilization exercise group. Each group will receive the same cervical stabilization exercises while group (1) will receive additional diaphragmatic resistance training as home program. All participants will have 2 evaluation sessions at baseline and after 6-week intervention for pain, disability and movement quality.
A clinical recommendation method, a clinical recommendation apparatus, and a computer-readable recording medium are provided. In the method, each medical parameter is determined as an independent event. Each medical parameter has an actual diagnosis. 
The independent event is defined that a medical parameter is independent of the actual diagnosis thereof. Multiple relation coefficients of each medical parameter are determined based on a probabilistic model. Each relation coefficient is a coefficient of one medical parameter in a condition where one reference diagnosis occurs. Multiple final coefficients of reference diagnoses are determined according to the relation coefficients of the medical parameters. A recommendation is determined according to the final coefficients of the reference diagnoses. Accordingly, a proper recommendation may be provided.
The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures. The static stretching technique is a widely used method that lengthens muscle length by autogenic inhibition that stimulates the Golgi tendon organ. This technique involves passively stretching a specific antagonist muscle by placing it in a position of maximum stretch and holding it there for an extended period of time. Recommendations on the optimal length of time to hold this flexed position typically indicate that a 30-second hold, repeated 3 to 4 times, will provide the most beneficial results. 3 repetitions of passive stretching for 30 seconds will be applied to the same structures.
<P>PROBLEM TO BE SOLVED: To develop a method for producing natural and modified Factor IX.  <P>SOLUTION: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals incorporating chimeric DNA molecules. Transgenic animals are obtained by introducing DNA encoding the Factor IX into developing embryos so that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature animal. Particularly efficient expression was accomplished by using a chimeric construct comprising a mammary gland-specific promotor, and the Factor IX cDNA lacking the complete or any portion of the 5'-untranslated and 3'-untranslated region, which is substituted with a 5'-end and 3'-end of the mouse whey acidic protein gene. In vitro cell cultures of cells transplanted from the transgenic mammal, methods for producing Factor IX from the cell cultures and methods for treating hemophilia B are also described.  <P>COPYRIGHT: (C)2010,JPO&INPIT